- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04504136
Regulation of Mucosal Healing in Inflammatory Bowel Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Induction of mucosal healing in inflammatory bowel disease (IBD) is associated with reduced hospitalizations, surgeries, and reduced cancer risk. However, previous studies have shown that 54-69% of ulcerative colitis (UC) patients fail to heal ulcers after several weeks of treatment, and roughly half do not maintain remission at one year. The single most important factor in preventing severe medical consequences, like colon removal surgery or cancer, is treatment to completely heal the top layer of the intestine as quickly as possible. Healing is a complex process and the dysfunction observed in colitis can only be fully understood by comparison to healing in non-IBD patients.
This is a prospective trial involving three groups of patients: 1) IBD patients with active disease, newly treated with anti-TNF therapy (biologic failure or naïve); 2) non-IBD patients with rheumatoid/psoriatic arthritis who are receiving anti-TNF therapy, and 3) healthy control patients. Biopsies will be collected at baseline during standard of care endoscopy and at a follow-up research endoscopy.
This study will probe mechanisms of ulcer healing by analyzing gene expression patterns and mitochondrial function.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Syed Adeel Hassan, MBBS/MD
- Phone Number: 312-340-4925
- Email: syed.hassan@uky.edu
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- Recruiting
- University of Kentucky
-
Contact:
- Syed Adeel Hassan, MBBS/MD
- Phone Number: 312-340-4925
- Email: syed.hassan@uky.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria (Group 1):
- Diagnosed ulcerative colitis or Crohn's disease
- Biologic failure or naive to biologic treatment
- Eligible to be treated with anti-TNF therapy
Inclusion Criteria (Group 2):
- Diagnosed rheumatoid or psoriatic arthritis
- Receiving anti-TNF antibody therapy at the time of enrollment
Inclusion Criteria (Group 3):
- Endoscopically unremarkable colonic mucosa
- Absence of inflammatory bowel disease
Exclusion Criteria:
- Classified in an anesthesia risk group, ASA Class =4
- History of bleeding diathesis or coagulopathy
- Stroke or transient neurological attack with the last 6 months
- Pregnant
- Receiving anticoagulants or anti-platelet medications other than low-dose aspirin
- Receiving steroid therapy or metformin
- HIV positive
- Incarceration
- History of total proctocolectomy
- History of system chemotherapy within 18 months
- Uncontrolled intercurrent illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy Controls
Participants in this group will be healthy (not diagnosed with inflammatory bowel disease).
|
During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed.
Patients will return for a follow-up colonoscopy 4-35 days later.
An additional 16-20 biopsies will be collected in a "biopsy of the biopsy" approach.
|
Experimental: Inflammatory Bowel Disease
Participants in this group will have been diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and have either failed treatment with biologics or be naive to biologic therapy.
|
During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed.
Patients will return for a follow-up colonoscopy 4-35 days later.
An additional 16-20 biopsies will be collected in a "biopsy of the biopsy" approach.
|
Experimental: Rheumatoid/Psoriatic Arthritis
Participants in this group will have been diagnosed with rheumatoid (RA) or psoriatic arthritis (PsA) and will be receiving anti-TNF antibody therapy at the time of enrollment.
|
During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed.
Patients will return for a follow-up colonoscopy 4-35 days later.
An additional 16-20 biopsies will be collected in a "biopsy of the biopsy" approach.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mitochondrial DNA copy number
Time Frame: 35 days
|
Mitochondrial DNA copy number will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
|
35 days
|
Change in expression levels of cMyc
Time Frame: 35 days
|
Relative expression of cMyc (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
|
35 days
|
Change in expression levels of PGC-1 alpha
Time Frame: 35 days
|
Relative expression of PGC-1 alpha (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
|
35 days
|
Change in expression levels of Ki67
Time Frame: 35 days
|
Relative expression of Ki67 alpha (mRNA) will be measured in epithelial cells collected from biopsies taken during the initial colonoscopy and at the follow-up colonoscopy.
|
35 days
|
Number of visible ulcers
Time Frame: 1 day (at follow-up visit)
|
The number of visible ulcers will be assessed during the follow-up endoscopy for healthy patients and rheumatoid/psoriatic arthritis patients only.
|
1 day (at follow-up visit)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Mayo Endoscopic Score
Time Frame: 35 days
|
The Mayo Endoscopic Score will be calculated at baseline and at follow-up in patients with ulcerative colitis only.
The Mayo Endoscopic score is evaluated for the macroscopically most severely inflamed segment: 0 for normal or inactive disease; 1 for erythema, decreased vascular pattern, mild friability; 2 for marked erythema, absent vascular pattern, friability, erosions; 3 ulcerations or spontaneous bleeding.
Segmental scores range from 0-3; higher scores indicate more severe disease.
|
35 days
|
Change in Segmental SES-CD Score
Time Frame: 35 days
|
The Simple Endoscopic Score (SES) will be calculated at baseline and follow-up in patients with Crohn's disease (CD) only.
The SES-CD score incorporates ulcer size, narrowing, and the area affected by disease or ulceration.
Scores range from 0-12; lower scores indicate remission while higher scores indicate severe endoscopic activity.
|
35 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fecal calprotectin levels
Time Frame: 35 days
|
Levels of fecal calprotectin (ug/g) will be measured from stool samples collected from patients at any time during the study protocol.
|
35 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Terrence Barrett, MD, University of Kentucky
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMDDN-20-MUCOSALHEALING
- 2R01DK095662-10A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on Serial Biopsy
-
British Columbia Cancer AgencyAmerican Society of Clinical Oncology; BC Cancer Foundation; Terry Fox Research... and other collaboratorsRecruitingCancer | Pancreatic CancerCanada
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingMicrosatellite Instability | Colorectal Cancer Stage IVUnited States
-
National Eye Institute (NEI)The Emmes Company, LLCCompletedRetinitis PigmentosaUnited States
-
National Eye Institute (NEI)The Emmes Company, LLCCompletedDiabetic Macular EdemaUnited States
-
Wake Forest University Health SciencesAmerican Heart AssociationCompletedChest Pain | Acute Coronary SyndromeUnited States
-
Sun Yat-sen UniversityGuangzhou Burning Rock Dx Co., Ltd.Active, not recruiting
-
Norfolk and Norwich University Hospitals NHS Foundation...University of East AngliaCompleted
-
University of Wisconsin, MadisonMerck Sharp & Dohme LLCCompleted
-
Centre hospitalier de l'Université de Montréal...Recruiting
-
John R van NagellRecruiting